Dynamk Capital

www.dynamk.vc

VCMatch tracks Dynamk Capital as an investor focused on Biotech, Medtech, and AI/ML companies and Seed and Series A rounds. Upload your deck to compare your startup against the full private matching profile.

Check Size

Not specified

Stages

Seed, Series A, Growth

Focus Areas

Biotech, Medtech, AI/ML

Geography

Not specified

Investment Thesis

Dynamk Capital focuses on providing early-stage and growth capital to companies that build enabling tools, technologies and services for the life sciences. They prioritize investments in disruptive platform technologies and service providers that accelerate R&D, development and manufacturing for biopharma customers, and they actively leverage an industry-heavy advisor network and operator experience to accelerate commercialization and exits for portfolio companies.

Is Dynamk Capital right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

Dynamk Capital is most relevant for founders raising Seed, Series A, and Growth rounds in Biotech, Medtech, AI/ML, and Enterprise SaaS.

Focus statement

Invests in Life Science tools and service providers — platform technologies, CRO/CDMO and manufacturing enablers, cell- and spatial-biology platforms, automation/AI for lab workflows, and other technologies that accelerate drug discovery, development and biomanufacturing.

Value Add

Explicit focus on tools & services rather than therapeutics ("Life Science tools and service providers").
Built-in operational expertise and exit experience via an advisor team of senior industry operators (examples include former leaders from Regeneron, Merck, Pfizer, and CMC/Biologics organizations).
Hands-on, sector-specific network and board/observer involvement across portfolio companies (multiple board/observer roles listed).
Track record of investing across both early-stage and growth rounds and co-leading strategic financings (e.g., co-leading Vernal Biosciences $21M round).
Emphasis on accelerating commercialization and getting technologies into the hands of customers (CDMO/CRO and manufacturing orientation).